Our recent addition to the MM Global Growth Portfolio RMD was the 2nd best performer on the ASX200 yesterday as investors appear to finally agree with the MM view that value has returned to the sleep disorder business following its 16% correction. We remain bullish with a break above $40 our preferred scenario into 2022 – this is one stock that hasn’t stayed down for long over recent years.
MM is bullish RMD targeting fresh highs into 2022 i.e. over 15% higher
Add To Hit List
